Healthcare Industry News: Scios
News Release - November 15, 2006
Bayhill Therapeutics Names Robert S. King Vice President of ManufacturingPALO ALTO, Calif.--(HSMN NewsFeed)--Bayhill Therapeutics Inc., a clinical stage biotechnology company developing innovative therapies for autoimmune diseases, has named Robert S. King, Ph.D. Vice President of Manufacturing. Dr. King will report to CEO Mark Schwartz and will be responsible for all manufacturing activities as the company moves its product candidates through clinical trials toward commercialization.
Dr. King brings more than 18 years of biotechnology industry experience to Bayhill. He most recently was the Vice President of Product Development and Manufacturing at Rinat Neuroscience Corp., a division of Pfizer Global Research and Development, where he was responsible for technical development of all product candidates. Previously, Dr. King was responsible for process development, formulations and manufacturing of all compounds in clinical development at Millennium Pharmaceuticals in South San Francisco and COR Therapeutics, where he oversaw product development of INTEGRILIN(TM) injection from proof of concept to commercialization. He also served in various product development roles at Scios Inc., formerly California Biotechnology Inc., and Molecular Devices Corp.
Dr. King holds several patents related to manufacturing processes and his work has been published in numerous scientific journals. He holds a Ph.D. in Chemical Engineering from the University of California, Berkeley and a Bachelor of Science degree in Chemical Engineering from the University of Washington.
"We are extremely pleased to have Robert join Bayhill Therapeutics' senior management team," Dr. Schwartz said. "Robert's breadth of manufacturing experience, including successfully moving product candidates through clinical trials to commercialization, will be invaluable to Bayhill as its antigen-specific DNA vaccines for multiple sclerosis and autoimmune diabetes progress through Phase II trials and potentially to market."
"Bayhill has made significant progress in moving its technology through clinical development," Dr. King commented. "I look forward to joining Bayhill's excellent management team in order to support the late-stage development and commercialization efforts of the company's exciting products."
About Bayhill Therapeutics
Bayhill Therapeutics Inc. is a clinical-stage biotechnology company focused on developing and commercializing therapeutics that fundamentally alter the way autoimmune diseases are treated. The company has developed two therapeutic platforms with broad applicability to a range of autoimmune diseases. Bayhill's BHT-DNA autoimmune vaccine is designed to eliminate disease-causing cells without affecting normal protective immune system cells. BHT-DNA is being studied in a Phase II trial for multiple sclerosis and a Phase I/II trial for autoimmune diabetes. Bayhill's second therapeutic is an oligonucleotide in preclinical development for systemic lupus erythematosus.
More information about Bayhill Therapeutics is available at www.bayhilltherapeutics.com.
Source: Bayhill Therapeutics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.